SCHEMBL5222368

SCHEMBL5222368

Cc1nc(-c2ccc(-c3ccc(CNCc4cn5c(C)cccc5n4)cc3)cc2)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.45
MAPT P10636 4/20 0.44
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
HDAC1 Q13547 6/20 0.41
HDAC8 Q9BY41 5/20 0.41
PLK1 P53350 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 2/20 0.39
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HDAC2 Q92769 3/20 0.38
TP53 P04637 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TPH1 P17752 1/20 0.37
TPH2 Q8IWU9 1/20 0.37
PDE10A Q9Y233 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5225829 0.81 HDAC1 (0.47) RAB9AMAPTKDM4EHDAC1HDAC8
SCHEMBL5222748 0.78 KDM4E (0.48) RAB9AMAPTKDM4EGAAHDAC1
SCHEMBL5225416 0.70 L3MBTL1 (0.43) MAPTHDAC1HDAC8L3MBTL1SMN1; SMN2
SCHEMBL5222506 0.70 L3MBTL1 (0.43) RAB9AMAPTHDAC1HDAC8PLK1
SCHEMBL632081 0.69 PLK1 (0.56) RAB9AMAPTHDAC1HDAC8PLK1
SCHEMBL5222143 0.69 HDAC1 (0.48) RAB9AHDAC1HDAC8PLK1L3MBTL1
SCHEMBL5226935 0.69 LMNA (0.41) MAPTKDM4EHDAC1HDAC8L3MBTL1
SCHEMBL6563104 0.68 L3MBTL1 (0.62) RAB9AMAPTHDAC1HDAC8L3MBTL1
SCHEMBL5224631 0.68 PLK1 (0.43) RAB9AHDAC1HDAC8PLK1L3MBTL1
SCHEMBL21702520 0.68 PLK1 (0.51) RAB9AHDAC1HDAC8PLK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771449-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP claimed
WO-2006011043-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO claimed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US claimed
EP-1771449-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP disclosed
WO-2006011043-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO disclosed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019998-A1 Histamine-3 receptor antagonist HRH3, HRH4, HRH2 RAB9A 295/4885MAPT 236/4885KDM4E 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.